Non-Small Cell Lung Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 13 – Jul 20, 2026
ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab.
J THORAC ONCOL · Q1 JOURNAL - RANK #3/108TOP-TIER
In this prospective multicenter study (NCT04392505), the primary objective was to evaluate a personalized tumor-agnostic ctDNA-based MRD assay for identifying patients with unresectable stage III NSCLC at high relapse risk after standard-of-care chemoradiotherapy plus durvalumab. The trial measured ctDNA detection at screening, after CRT, and during and after durvalumab in 659 plasma samples from 84 patients. Detectable ctDNA prior to the seventh durvalumab cycle (HR: 2.45, 95% CI: 1.18-5.11, p=0.013) and 3 months post-treatment (HR: 5.37, 95% CI: 1.93-14.93, p<0.001) predicted shorter progression-free survival. Researchers concluded that serial ctDNA-based MRD assessment may help guide targeted or intensified treatments to reduce the risk of early relapse.
10.1016/j.jtho.2026.103992
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART).
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This multicenter, single-arm, prospective phase II trial evaluated thoracic radiation plus concurrent and up to 12 months of consolidative durvalumab (1,500 mg every 4 weeks) in cCRT-ineligible patients with inoperable, locally advanced NSCLC. The primary endpoint targeted a 2-year PFS of 36% versus historical 20% with sequential CRT; 58 patients (median age 82) received conventionally fractionated RT and durvalumab, and associations with ECOG and PD-L1 were explored. The study met its primary endpoint with 2-year PFS 39% (one-sided CI 29–100) and reported 2-year OS 54%; grade 3/4 treatment-related AEs occurred in 21%, grade 5 in 7% (radiation pneumonitis n=2, cardiac arrest n=2), with durvalumab discontinued due to AEs in 31%. Better performance status and PD-L1 positivity correlated with improved PFS/CSS, supporting durvalumab with RT as a promising option for cCRT-ineligible LA-NSCLC.
10.1200/JCO-25-02517
Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14).
FRONT IMMUNOL · Q1 JOURNAL - RANK #32/183
This study analyzes longitudinal extracellular vesicle (EV) dynamics as prognostic biomarkers in a prospective single-arm phase II clinical trial (SAKK 16/14) of neoadjuvant chemoimmunotherapy (cisplatin, docetaxel, durvalumab) followed by surgery and adjuvant durvalumab in patients with resectable stage IIIA (N2) non-small-cell lung cancer. Serum samples were collected at five time points; EV markers (PD-L1, PanEV, PanCK, EpCAM, CD45) were assessed via flow cytometry after galectin-based isolation, with nanoparticle tracking analysis and electron microscopy confirming successful isolation. Results showed a trend of decreasing EV-MFI after initial therapy; elevated post-therapeutic PanEV/PanCK double-positive EV levels were significantly associated with reduced event-free survival (p=0.001) and overall survival (p=0.003). The study concludes that EV-based liquid biopsies offer complementary prognostic information in heterogeneous cancer stages, supporting personalized treatment strategies.
10.3389/fimmu.2026.1807542
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial.
JAMA SURG · Q1 JOURNAL - RANK #1/312TOP-TIER
This multicenter, double-blind, placebo-controlled phase 3 randomized trial (Neotorch, NCT04158440) enrolled 404 patients with resectable stage III NSCLC, randomizing them 1:1 to three neoadjuvant and one adjuvant cycle of toripalimab (240 mg) plus platinum-based chemotherapy versus placebo plus chemotherapy, followed by 13 maintenance cycles of either toripalimab or placebo. Among 314 operated patients (166 vs 148), the toripalimab group had fewer surgery cancellations (17.8% vs 26.7%; P = .03), higher tumor downstaging (80.7% vs 50.7%; P < .001) and lymph-node downstaging (67.5% vs 48.6%; P = .001), with similar perioperative complication rates. After a median 18.3-month follow-up, toripalimab improved event-free survival, particularly in patients achieving tumor or nodal downstaging (median EFS not estimable vs 17.5–22.0 months; P values .004–.009). The authors conclude that perioperative toripalimab plus chemotherapy offers comparable surgical safety and confers superior downstaging and EFS benefits in resectable stage III NSCLC.
10.1001/jamasurg.2026.2711
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50.
J THORAC ONCOL · Q1 JOURNAL - RANK #3/108TOP-TIER
This phase 3 randomized trial evaluated ociperlimab plus tislelizumab versus pembrolizumab and tislelizumab in 662 previously untreated patients with locally advanced or metastatic NSCLC with PD-L1 ≥50%. Patients were randomized 5:5:2 to one of the three arms, and the primary endpoint was overall survival (OS), with secondary endpoints including progression-free survival (PFS) and overall response rate (ORR). The interim analysis found median OS for arms A (ociperlimab+tislelizumab), B (pembrolizumab), and C (tislelizumab) to be 31.9, 29.4, and 27.7 months, respectively, with a stratified hazard ratio for A vs B of 0.97 (95% CI: 0.76–1.23), while PFS and ORR results did not indicate clear superiority. The combination therapy did not improve OS compared to pembrolizumab, and all arms showed acceptable safety profiles.
10.1016/j.jtho.2026.104089
Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This single-arm phase II trial (NCT05383716) evaluated neoadjuvant pembrolizumab plus platinum-based chemotherapy in 80 patients with resectable NSCLC, followed by surgery and adjuvant immunotherapy, with a primary endpoint of major pathological response (MPR). Among 55 patients who underwent surgery, MPR rate was 37.5% and pathological complete response rate was 26.3%, with grade 3-4 adverse events in 26.3% of patients. Spatial transcriptomics revealed MPR tumors were enriched for T- and B-cell activation pathways, while non-MPR tumors showed immune suppression signatures, with two immune phenotypes (myeloid-enriched and lymphoid-enriched) identified. The study concluded that neoadjuvant chemoimmunotherapy is effective and safe, with distinct immune phenotypes potentially guiding adjuvant therapy stratification.
10.1158/1078-0432.CCR-25-4222
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This phase II, open-label study evaluated the efficacy and safety of osimertinib plus gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) harboring the EGFR C797X mutation after progression on first-line osimertinib (NCT03944772). The study included 31 patients, achieving an objective response rate (ORR) of 26% (80% CI: 16-39) and a median progression-free survival (PFS) of 5.1 months (95% CI: 3.9-6.8), while median overall survival was 19.0 months (95% CI: 14.6-25.0). Safety was consistent with known drug profiles, with 35% experiencing grade ≥3 adverse events. Although the regimen demonstrated modest benefits, its risk-benefit profile suggests further evaluation is unwarranted for this population.
10.1158/1078-0432.CCR-26-0704
Holistic oncologic management improves quality of life in driver gene negative advanced NSCLC a latent growth curve modeling study.
SCI REP-UK · Q1 JOURNAL - RANK #25/135
Holistic Oncologic Management (HOM) was compared to standard care for advanced driver-gene-negative NSCLC in a randomized controlled trial from October 2019 to July 2023. The study enrolled 158 participants (81 in the control group and 77 in the treatment group) who received HOM focusing on quality of life (QoL), depression, pain, and nutrition over 24 consecutive weeks. Six-point QoL trajectories based on latent growth curve modeling showed significant improvements in QoL, pain control, nutritional status, and mood, with younger patients benefiting more. The authors conclude that HOM meaningfully enhances outcomes in advanced NSCLC.
10.1038/s41598-026-62103-3
Jul 06 – Jul 13, 2026
Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431.
J THORAC ONCOL · Q1 JOURNAL - RANK #3/108TOP-TIER
This study aimed to evaluate the outcomes of chemoimmunotherapy and chemotherapy alone in patients with RET fusion-positive lung cancer within the phase 3 LIBRETTO-431 clinical trial. A total of 83 patients received chemoimmunotherapy, and 19 received chemotherapy alone. Progression-free survival (PFS) and overall survival (OS) were not significantly different between the two groups, with median PFS by BICR of 11.2 months for chemoimmunotherapy patients, and OS not reached in either group. The results suggest that chemotherapy alone is a reasonable first-line strategy for oncogene-driven RET fusion-positive lung cancer, with selective RET inhibitors being the preferred treatment option as supported by the broader findings from the trial.
10.1016/j.jtho.2026.104086
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.
J HEMATOL ONCOL · Q1 JOURNAL - RANK #1/98TOP-TIER
This multicenter phase 1/2a clinical trial evaluated visugromab, an anti-GDF-15 antibody, plus nivolumab in 77 patients with anti-PD-1/PD-L1-relapsed/refractory locally advanced/metastatic non-squamous NSCLC, urothelial carcinoma, or hepatocellular carcinoma. Patients received both drugs every two weeks until progression or unacceptable toxicity, and responses were assessed via RECIST v1.1. Objective response rates were 18.2% (NSCLC), 18.5% (UC), and 14.3% (HCC), with median duration of response ranging from 19.4 to 32.2 months and 53.8% of responses ongoing; 61.5% achieved confirmed complete or metabolic response. The study concludes that GDF-15 blockade with visugromab enhances response rates and durability versus prior anti-PD-1/PD-L1 therapy, suggesting its value for further randomized investigation.
10.1186/s13045-026-01818-2
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).
J THORAC ONCOL · Q1 JOURNAL - RANK #3/108TOP-TIER
This randomized, double-blind, phase 3 trial evaluated niraparib-plus-pembrolizumab versus placebo-plus-pembrolizumab as maintenance therapy in 666 adults with advanced/metastatic NSCLC lacking targetable driver alterations (ClinicalTrials.gov: NCT04475939). Patients responded to initial chemotherapy plus pembrolizumab and were then randomized (1:1) to either treatment, with the primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR). Median PFS for the complete/partial response group was identical in both arms at 5.55 months (HR 1.00, 95% CI 0.79-1.27; 1-sided p=0.502), and no improvements in efficacy were observed; common grade ≥3 hematologic adverse events included anemia, thrombocytopenia, and neutropenia. The study concluded that niraparib addition did not improve efficacy or lead to new safety signals in this population.
10.1016/j.jtho.2026.104087
Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
The study aimed to identify plasma protein biomarkers predictive of pathological complete response (pCR) to neoadjuvant immunochemotherapy (nICT) in resectable non-small cell lung cancer (NSCLC) and explore resistance mechanisms. Pretreatment plasma samples from 86 patients were analyzed using Olink assays, with predictive models developed via logistic regression, random forest, and XGBoost, validated internally (AUC=0.845) and externally (AUC=0.801). Elevated baseline LIF levels were associated with inferior survival (OS HR=13.003, PFS HR=3.75) and reduced CD8+ T-cell infiltration, while murine models showed LIF blockade enhanced therapy efficacy. The study concludes that plasma proteomics can predict nICT response and highlights LIF as a therapeutic target, warranting prospective validation.
10.1136/jitc-2026-015312
Jun 29 – Jul 06, 2026
Single Percussive Ventilation Breath-hold Imaging and Delivery in Lung Tumor Stereotactic Ablative Radiation Therapy: Initial Observations From a Prospective Clinical Trial.
INT J RADIAT ONCOL · Q1 JOURNAL - RANK #14/212
This study’s primary objective was to evaluate the feasibility and safety of percussive ventilation breath-hold (PVB) in enhancing stereotactic ablative radiation therapy (SABR) for lung cancer patients by ensuring reproducible breath-holds. Four patients with lung tumors participated in a prospective, IRB-approved clinical trial involving tolerance assessment for PVB, followed by PVB-SABR treatment. Results demonstrated that all patients successfully completed the protocol, with a mean PVB duration of 6 minutes 56 seconds, a mean SABR delivery time of 2 minutes 22 seconds, and a mean duty cycle of 93.5%. The study concludes that PVB can allow completion of SABR delivery and confirmatory imaging in a single breath-hold, eliminating uncertainty of inter-breath-hold variability.
10.1016/j.ijrobp.2026.05.034
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This study is a post-hoc analysis of the phase 3 randomized, double-blind, placebo-controlled PACIFIC trial, evaluating the impact of baseline proton pump inhibitor (PPI) and antibiotic exposure on the efficacy of durvalumab treatment in 660 patients with unresectable stage III non-small cell lung cancer (NSCLC) previously treated with chemoradiotherapy. The analysis found that baseline PPI exposure was associated with shorter progression-free survival (9.4 vs. 17.2 months, HR 1.57, p<0.0001) and overall survival (33.0 vs. 57.9 months, HR 1.66, p<0.0001) in the durvalumab group, whereas baseline antibiotic exposure was associated with shorter progression-free survival (9.2 vs. 15.6 months, HR 1.50, p=0.016) but no significant change in overall survival. No such associations were observed in the placebo group. The study concluded that PPI and antibiotics might attenuate the therapeutic benefit of durvalumab in this patient population.
10.1016/S1470-2045(26)00191-9
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.
CELL REP MED · Q1 JOURNAL - RANK #15/195TOP-TIER
This phase II clinical trial investigates the efficacy and safety of high-dose furmonertinib (160 mg daily) as a first-line treatment for 40 patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases. At a median follow-up of 18.66 months, the study reports a median progression-free survival (mPFS) of 16.59 months (95% CI: 12.77-20.41) and an intracranial progression-free survival of 17.83 months (95% CI: 14.16-21.50). Systemic objective response rate (ORR) and intracranial ORR were 92.5% and 95.0%, respectively, while grade ≥3 treatment-related adverse events occurred in 15% of patients. The study concludes that furmonertinib exhibits strong intracranial efficacy with a favorable safety profile in patients with EGFR-mutated NSCLC and CNS metastases.
10.1016/j.xcrm.2026.102904
Jun 22 – Jun 29, 2026
Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This prospective, interventional basket trial (DRUP; NCT02925234) evaluated trametinib monotherapy in patients with progressive advanced/metastatic NRAS-mutated solid tumors who had exhausted standard options, with whole-genome sequencing on pre-treatment biopsies and primary endpoints of RECIST v1.1-defined clinical benefit (CB) and safety. Twenty-four evaluable patients were treated between January 2017 and February 2024; CB occurred in 9/24 (37.5%) with one partial response (4.2%). Median overall survival was 9.0 months (95% CI 5.6–13.5) and median progression-free survival was 3.7 months (95% CI 3.3–5.3); outcomes did not differ by NRAS codon (Q61 vs G12/13) or tumor type (NSCLC vs others), and no unexpected toxicities were observed. The study concludes trametinib provides limited clinical benefit in NRAS-mutant malignancies and calls for biomarker refinement.
10.1016/j.ejca.2026.116906
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.
LUNG CANCER · Q1 JOURNAL - RANK #19/108
This open-label, phase 2 module of the ORCHARD platform trial evaluated durvalumab 1,500 mg IV every 3 weeks plus etoposide-platinum every 3 weeks (up to four cycles; durvalumab continued until progression/toxicity) in EGFR-mutated advanced NSCLC with neuroendocrine transformation after progression on first-line osimertinib. The primary endpoint was investigator-assessed ORR per RECIST 1.1, with secondary endpoints of PFS, DoR, OS, and safety; 14 patients were treated and evaluable. Confirmed ORR was 43% (80% CI 24–63) with six partial responses; median DoR was 4.3 months (95% CI 3.0–not calculable), median PFS 4.2 months (95% CI 3.0–5.6), and median OS 10.2 months (95% CI 4.3–16.8). Grade ≥3 AEs occurred in 64% (most commonly neutropenia/decreased neutrophils), and the regimen produced modest activity without new safety signals.
10.1016/j.lungcan.2026.109501
Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.
J THORAC ONCOL · Q1 JOURNAL - RANK #3/108TOP-TIER
This prospective, multicenter, single-arm phase II trial (NCT04882345) evaluated aumolertinib 110 mg daily in patients with EGFR-mutant advanced NSCLC who developed grade ≥2 hematologic toxicities or moderate/severe adverse events on osimertinib. The primary endpoint was the 3-month conversion success rate, with 34 of 39 patients who switched being evaluable. Results showed a 3-month conversion success rate of 70.6% (95% CI: 52.5, 84.9), median post-switch progression-free survival of 11.6 months, and a 3-year overall survival rate of 52.4%. Switching to aumolertinib maintained clinical benefits with a manageable safety profile, suggesting this strategy is feasible for osimertinib-intolerant patients.
10.1016/j.jtho.2026.104062
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This study analyzed pooled data from the phase III IMpower130 and IMpower150 trials to evaluate whether VEGF-A blockade with bevacizumab overcomes liver metastasis resistance to chemoimmunotherapy in advanced non-squamous NSCLC. Among 1,713 patients, 236 had liver metastases. In IMpower130, no overall survival benefit was seen with atezolizumab plus chemotherapy (HR 1.05). In IMpower150, adding bevacizumab to atezolizumab plus chemotherapy significantly improved progression-free survival (HR 0.49) and overall survival (HR 0.52) in liver-metastatic patients. The authors conclude that bevacizumab may disrupt VEGF-A-driven immunosuppression in the liver, but require prospective confirmation.
10.1136/jitc-2026-014991
Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).
CANCER IMMUNOL IMMUN · Q1 JOURNAL - RANK #68/326
This phase II single-arm clinical trial investigated the safety and efficacy of first-line durvalumab combined with platinum-etoposide in patients with advanced large-cell neuroendocrine carcinoma (aLCNEC). The primary endpoint was 12-month progression-free survival (PFS), with secondary endpoints including overall response rate (ORR), overall survival (OS), and safety. Out of 12 enrolled patients (median age 68; 92% smokers; 92% with disease progression), the 12-month PFS was 25.0% (95% CI 6.0-50.5%), exceeding the null hypothesis threshold, while the 12-month OS was 58.3% (95% CI 27.0-80.1%). The treatment showed manageable toxicity with efficacy consistent with the study design, despite early study closure due to low enrollment.
10.1007/s00262-026-04464-2
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This single-arm, prospective phase II trial (RECLAIM) enrolled 31 patients with metastatic non-small cell lung cancer showing low (<50%) or negative (<1%) PD-L1 expression who had progressed after first-line anti-PD-1 therapy. Participants received ipilimumab 1 mg/kg every six weeks plus nivolumab (240 mg q2w ×6 weeks then 360 mg q3w) combined with subablative radiotherapy (3 × 8 Gy to 1–4 lesions). At weeks 6 and 12, objective response rates were 7 % and 10 %, respectively, with a best ORR of 29 % and disease control rates of 58 % and 39 %. Median overall survival varied with best response: 3.1 months (PD), 13.5 months (SD) and 22.5 months (PR/CR); 26 % experienced grade 3 adverse events and 16 % discontinued due to immune-related toxicity. The study concludes that combined IPI/NIVO with radiotherapy can rescue a subset of anti-PD-1-refractory NSCLC patients, eliciting durable responses with manageable safety and marked peripheral T-cell activation.
10.1136/jitc-2025-014724
Jun 15 – Jun 22, 2026
Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This single-arm phase II trial evaluated neoadjuvant camrelizumab plus chemotherapy in 30 patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The primary endpoint was pathological complete response (pCR), with secondary endpoints including major pathological response (MPR), disease-free survival (DFS), and safety. pCR and MPR rates were 33.3% and 50.0%, respectively; at a median follow-up of 27.2 months, the 2-year DFS rate was 77.4%, and grade≥3 treatment-related adverse events occurred in 13.3%. Exploratory biomarker analyses identified baseline CD8+ naïve-like T-cell abundance, circulating CCL3 levels, and ctDNA dynamics as potential prognostic biomarkers.
10.1136/jitc-2026-015604
A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB-IIIB Lung Squamous Cell Carcinoma.
MEDCOMM · Q1 JOURNAL - RANK #14/195TOP-TIER
This phase II, single-arm prospective trial enrolled 45 patients with resectable stage IIB-IIIB lung squamous cell carcinoma to receive two 3-week cycles of neoadjuvant camrelizumab 200 mg plus nab-paclitaxel and carboplatin, followed by surgery and one year of adjuvant camrelizumab. The primary endpoint was major pathological response (MPR); secondary endpoints included pathological complete response (pCR), 3-year disease-free survival (DFS) and overall survival (OS), alongside exploratory blood-based biomarker analyses. MPR was achieved in 27/45 patients (60.0 %) and pCR in 20/45 (44.4 %); with 37.5 months median follow-up, 3-year DFS and OS were 65.9 % and 68.7 %, respectively, and stage IIIB patients showed 37.5 % pCR. The authors conclude perioperative camrelizumab plus chemotherapy is effective in locally advanced LUSC and that baseline neutrophil percentage, smoking status, and specific TCR V-J pairs merit further study as predictive biomarkers.
10.1002/mco2.70793
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This randomized, double-blind, placebo-controlled phase 3 trial (HARMONi-A; NCT05184712) evaluated whether adding the bispecific antibody ivonescimab to standard pemetrexed–carboplatin chemotherapy improves survival in adults with locally advanced or metastatic EGFR-variant nonsquamous NSCLC that progressed after EGFR-TKI therapy. Between January and November 2022, 322 Chinese patients were randomized 1:1 to ivonescimab 20 mg/kg or placebo alongside four induction cycles of chemotherapy followed by maintenance, with overall survival (OS) assessed hierarchically after PFS. After a median 32.5-month follow-up, median OS was 16.8 months in the ivonescimab arm versus 14.1 months with chemotherapy alone (stratified HR 0.74, 95% CI 0.58–0.95; P = .02), and 30-month OS rates were 29.1% vs 18.4%. Grade ≥3 treatment-emergent adverse events occurred in 67.1% vs 54.7%, yet investigators concluded that ivonescimab plus chemotherapy confers statistically significant and clinically meaningful survival benefit with an acceptable safety profile in this difficult-to-treat population.
10.1001/jama.2026.7745
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial.
SIGNAL TRANSDUCT TAR · Q1 JOURNAL - RANK #1/319TOP-TIER
The TRAILBLAZER phase 2 study (NCT04580498) evaluated the neoadjuvant use of retlirafusp alfa (anti-PD-L1/TGF-β bifunctional agent) with or without chemotherapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) without EGFR or ALK alterations. Patients were stratified by PD-L1 expression with 88 receiving the agent plus chemotherapy (arm A), and 19 receiving either combination therapy (arm B) or monotherapy (arm C). At 39.4 months’ median follow-up, the 3-year EFS was 50.5% (95% CI 39.0-61.0) in arms A + B and 77.1% (95% CI 34.5-93.9) in arm C, while 3-year OS rates were 68.3% (95% CI 57.5-77.0) and 87.5% (95% CI 38.7-98.1), respectively. Updated findings confirm the survival benefits and safety of the regimen, highlighting the potential of neoadjuvant immunotherapy with surgery for unresectable stage III NSCLC.
10.1038/s41392-026-02779-1
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This open-label, multicentre, randomised controlled phase 3 trial enrolled 624 treatment-naïve adults with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer to receive either aumolertinib 110 mg daily plus platinum-pemetrexed chemotherapy or aumolertinib monotherapy. Patients were stratified by mutation type and brain-metastasis status; the primary endpoint was BICR-assessed progression-free survival (PFS). After a median 23.4-month follow-up, median PFS was 28.9 months (95 % CI 26.3–NA) with combination therapy versus 18.9 months (17.8–21.1) with monotherapy (HR 0.47, 95 % CI 0.37–0.60; p<0.0001). Combination therapy generated higher grade 3–4 haematologic toxicity (e.g., neutropenia 55 % vs 1 %), but adverse events were manageable, and the regimen significantly prolonged PFS compared with single-agent aumolertinib.
10.1016/S1470-2045(26)00090-2
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J THORAC ONCOL · Q1 JOURNAL - RANK #3/108TOP-TIER
The EMPOWER-Lung 3 Part 2 trial is a prospective, phase 3 study that randomized 466 patients with advanced NSCLC without EGFR, ALK, or ROS1 aberrations to cemiplimab plus chemotherapy (n=312) or chemotherapy alone (n=154). The primary endpoint was overall survival (OS), with key secondary endpoints including PFS and ORR. After a median follow-up of 60.9 months, the combination arm showed a significantly improved median OS of 21.1 months vs. 12.9 months (HR 0.66, p=0.0002), a median PFS of 8.2 vs. 5.5 months (HR 0.58, p<0.0001), and a higher ORR of 43.6% vs. 22.1%. The study concludes that long-term efficacy and manageable safety were demonstrated with cemiplimab plus chemotherapy as a first-line treatment option.
10.1016/j.jtho.2026.103980
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.
LUNG CANCER · Q1 JOURNAL - RANK #19/108
The LAURA phase III trial evaluated osimertinib versus placebo after definitive chemoradiotherapy (CRT) in 216 patients with unresectable stage III EGFR-mutated NSCLC. Patients were randomized 2:1 to osimertinib (n=143) or placebo (n=73), with safety assessed at scheduled intervals. Key findings included median exposure of 24.0 vs 8.3 months, exposure-adjusted grade ≥3 adverse event rates of 18 vs 13 per 100 patient-years, and treatment discontinuation in 13% vs 5%. The study concluded osimertinib had an acceptable safety profile, supporting its use as a new standard of care in this setting.
10.1016/j.lungcan.2026.109486
Jun 08 – Jun 15, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.
CANCER COMMUN · Q1 JOURNAL - RANK #12/326TOP-TIER
Phase III ASTRUM-002 randomized 636 treatment-naïve patients with locally advanced/metastatic nonsquamous NSCLC without EGFR/ALK/ROS1 alterations 1:1:1 to serplulimab+bevacizumab biosimilar (HLX04)+chemotherapy, serplulimab+placebo+chemotherapy, or double placebo+chemotherapy in a double-blind design; primary endpoint was PFS, key secondary OS. At final analysis, median OS was 23.7 months (95% CI 20.5–27.5), 26.8 months (21.2–30.9), and 20.3 months (16.2–24.6) in groups A, B, and C, respectively. Serplulimab+chemotherapy significantly reduced risk of death vs chemotherapy (B vs C HR 0.66, 95% CI 0.52–0.83; p<0.001), with crossover-adjusted HRs 0.53 (two-stage; 95% CI 0.42–0.68; p<0.001) and 0.65 (RPSFT; 95% CI 0.51–0.83; p<0.001). Adding HLX04 to serplulimab+chemotherapy did not improve OS (A vs B HR 1.12, 95% CI 0.88–1.42; p=0.363), supporting serplulimab+chemotherapy as an effective first-line option.
10.34133/cancomm.0034
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This phase II clinical trial evaluated the efficacy and safety of cadonilimab plus chemotherapy as first-line treatment for PD-L1-negative advanced non-small-cell lung cancer (NSCLC). The study achieved its primary endpoint with a 12-month progression-free survival (PFS) rate of 42.1% (95% CI, 29.6%-60.0%), alongside secondary outcomes including a median PFS of 9.7 months, objective response rate of 66.0%, and disease control rate of 100.0%. Grade ≥3 treatment-related adverse events occurred in 52.0% of patients, and cfDNA methylation-based molecular response predicted clinical response earlier than radiographic evaluation. The findings suggest cadonilimab plus chemotherapy is effective and manageable for PD-L1-negative advanced NSCLC, warranting further controlled studies.
10.1038/s41467-026-74241-3
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This study aimed to evaluate prognostic and predictive factors (tumor burden and BMI) for alectinib efficacy in ALK-positive NSCLC, using a pooled individual patient-level analysis from two randomized phase III clinical trials, ALEX and J-ALEX (total n=500; alectinib n=249, crizotinib n=251). Methodology included multivariate Cox regression and random effects modeling, analyzing progression-free survival (PFS) and overall survival (OS). Alectinib significantly improved PFS over crizotinib (HR 0.41, 95%CI 0.31-0.55, p<0.001) while high tumor burden was associated with shorter PFS and OS; BMI>25 kg/m2 was linked to longer OS but not PFS. The authors conclude tumor burden is both prognostic and predictive for ALK-positive NSCLC, suggesting treatment intensification may benefit patients with high tumor burden.
10.1016/j.ejca.2026.116867
Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).
LUNG CANCER · Q1 JOURNAL - RANK #19/108
This multicenter, single-arm phase II prospective clinical trial assessed docetaxel plus ramucirumab in 33 patients with advanced NSCLC who progressed after immune checkpoint inhibitor regimens. Patients received docetaxel 60 mg/m² and ramucirumab 10 mg/kg every 3 weeks, with primary endpoint objective response rate (ORR; 33.3%, 90% CI 19.9-49.1) and secondary endpoints including progression-free survival (4.9 months, 95% CI 4.4-6.2) and overall survival (11.8 months, 95% CI 9.8-18.8). Disease control rate was 90.9% (90% CI 78.1-97.5), and patients who previously responded to immunotherapy had significantly longer PFS (HR 0.34, 95% CI 0.14-0.76). Although the primary endpoint was not met, the regimen showed antitumor activity and manageable safety in the post-ICI setting.
10.1016/j.lungcan.2026.109454
Low-Dose SBRT-Based Radiotherapy Followed by Pembrolizumab and Chemotherapy for Potentially Resectable NSCLC: A Phase Ib Study.
INT J RADIAT ONCOL · Q1 JOURNAL - RANK #14/212
This phase Ib study evaluated the safety and surgical conversion of neoadjuvant low-dose SBRT-based radiotherapy followed by pembrolizumab and chemotherapy in 17 patients with potentially resectable stage III NSCLC. The treatment involved 24 Gy (peripheral) or 12 Gy (central) SBRT in three fractions, followed by two cycles of pembrolizumab plus chemotherapy, with surgical feasibility assessed 4-6 weeks post-therapy. Key results included no dose-limiting toxicities, 29.4% grade 3-5 adverse events, 94.1% objective response, 64.7% surgical success (90.9% R0 resection), and 54.5% pCR, with median PFS of 29.0 months and OS of 37.9 months. The regimen was deemed tolerable with promising efficacy for surgical conversion and pathological response.
10.1016/j.ijrobp.2026.05.055
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China.
ECLINICALMEDICINE · Q1 JOURNAL - RANK #11/332
This single-arm, open-label, phase II trial evaluated neoadjuvant sintilimab plus chemotherapy in 35 patients with resectable stage II-IIIB EGFR-mutant NSCLC. The primary endpoint, major pathological response (MPR), was 34.3% (95% CI 19.1-52.2). Secondary endpoints included objective response rate (60.0%), pathological complete response (11.4%), and a 2-year event-free survival rate of 71.4% (95% CI 57.9-88.1%). The authors conclude this combination demonstrates encouraging clinical and pathological response with acceptable tolerability, warranting further randomized controlled trials.
10.1016/j.eclinm.2026.103994
Jun 01 – Jun 08, 2026
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.
JCO ONCOL PRACT · Q1 JOURNAL - RANK #81/326
This phase II, open-label, crossover study (NCT06099782) evaluated participant preference for subcutaneous (SC) versus intravenous (IV) pembrolizumab in 147 patients with resected melanoma, renal cell carcinoma, or metastatic non-small cell lung cancer. Participants were randomized 1:1 to SC (395 mg) or IV (200 mg) pembrolizumab for three cycles before crossover, with preference assessed via Patient Preference Questionnaire. Results showed 65% (95% CI: 56-74) preferred SC, citing less clinic time (64%), and 68% chose SC for continued treatment; grade 3-4 AEs occurred in 1% (SC) and 7% (IV) during initial cycles. The study concluded SC pembrolizumab offers greater convenience and comparable safety to IV administration in cancer treatment.
10.1200/OP-25-01248
Robust Findings for HER2 TKI in NSCLC.
CANCER DISCOV · Q1 JOURNAL - RANK #10/326TOP-TIER
This study evaluates the clinical efficacy of zongertinib, a HER2 tyrosine kinase inhibitor (TKI), in treating HER2-mutant non-small cell lung cancer (NSCLC). Among 74 patients who received a daily dose, the objective response rate was 76%, and the median progression-free survival was 14.4 months, significantly outperforming traditional chemotherapy response rates of approximately 30% and a median duration of under 7 months. The findings suggest that zongertinib offers a notable improvement compared to the standard treatment options. These results highlight the potential of targeted therapies in advancing the treatment landscape for HER2-mutant NSCLC patients.
10.1158/2159-8290.CD-NW2026-0051
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This open-label, randomized phase 3 clinical trial evaluated adjuvant nivolumab versus observation in 935 patients with resected non-small cell lung cancer (NSCLC) following planned adjuvant therapy. Patients were randomized 1:1 to receive nivolumab 480 mg intravenously every 4 weeks for up to 1 year or standard observation, with co-primary endpoints of disease-free survival (DFS) in the intention-to-treat population and in those with PD-L1 ≥50%. After median 72.6 months follow-up, median DFS was 71.3 months with nivolumab vs 68.8 months with observation (HR 0.97; 95% CI 0.81-1.17; p=0.39), and in the PD-L1 ≥50% subset, 89.8 vs 78.5 months (HR 0.86; 95% CI 0.59-1.25; p=0.22). The authors concluded adjuvant nivolumab did not improve DFS in this patient population.
10.1001/jama.2026.8992
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
HARMONi-6 is a randomized, double-blind, phase 3 trial at 50 Chinese hospitals comparing ivonescimab plus paclitaxel/carboplatin (four cycles) followed by ivonescimab maintenance versus tislelizumab plus the same chemotherapy and tislelizumab maintenance in previously untreated advanced squamous NSCLC. 532 patients were randomized (266/266), median age 64 (IQR 59–69), 93% male; the prespecified interim overall survival analysis was conducted after 204 deaths with a median follow-up of 21.4 months. Ivonescimab improved median overall survival to 27.9 months (95% CI 27.89–NE) versus 23.7 months (20.11–NE) with tislelizumab (HR 0.66, 95% CI 0.50–0.87; p=0.0017), with grade ≥3 treatment-related adverse events in 69% vs 59% and grade ≥3 hemorrhage in 3% vs 1%. Investigators concluded ivonescimab plus chemotherapy confers a statistically significant and clinically meaningful overall survival benefit as first-line therapy in advanced squamous NSCLC.
10.1016/S0140-6736(26)00966-9
May 25 – Jun 01, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
The study aimed to evaluate the long-term efficacy and safety of lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer (NSCLC) over 7 years in the phase 3 CROWN trial. A total of 296 treatment-naive patients were randomized 1:1 to receive lorlatinib (100 mg OD) or crizotinib (250 mg BID), with investigator-assessed outcomes including progression-free survival (PFS), safety, and biomarker analyses. At median follow-ups of 83.0 and 77.2 months, median PFS was not reached (NR; 68.5-NR) for lorlatinib versus 9.1 months (7.4-10.9) for crizotinib (HR 0.19; 95% CI 0.13-0.26), with 7-year PFS rates of 55% and 3%, respectively. The safety profile remained consistent with prior findings, and lorlatinib demonstrated sustained long-term disease control, suggesting potential for advanced ALK-positive NSCLC to become a chronic condition.
10.1016/j.annonc.2026.05.692
First-line envafolimab plus recombinant human-endostatin in advanced non-small cell lung cancer with PD-L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single-arm, phase 2 trial.
CANCER-AM CANCER SOC · Q1 JOURNAL - RANK #68/326
This multicenter, prospective, single-arm, phase 2 trial evaluated the efficacy and safety of envafolimab plus recombinant human endostatin (Rh-endostatin) in 33 treatment-naive advanced NSCLC patients with PD-L1-positive and no driver gene mutations. Patients received treatment every 21 days until disease progression or intolerable toxicity, with primary endpoints being objective response rate (ORR) and safety, and secondary endpoints including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). The ORR was 48.5% (95% CI, 30.8%-66.5%), DCR was 81.8% (95% CI, 64.5%-93.0%), median PFS was 12.3 months (95% CI, 3.1-21.5 months), and 1-year OS rate was 73.9%, with no grade 4 or 5 adverse events reported. The study concluded that the combination demonstrated favorable efficacy and tolerable toxicity in this patient population, supported by exploratory biomarker analysis showing AUC values of 0.77 for MMP1 and 0.68 for TNFRSF6B.
10.1002/cncr.70479
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
The study evaluated the efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab versus pembrolizumab alone as first-line treatment for PD-L1-positive advanced non-small-cell lung cancer (NSCLC) in a randomized, open-label, phase 3 trial. A total of 413 patients were assigned to sac-TMT plus pembrolizumab (n=208) or pembrolizumab alone (n=205), with a median follow-up of 10.5 months. The combination therapy significantly improved progression-free survival (not reached vs 5.7 months; HR 0.35, 95% CI 0.26-0.47, p<0.0001) and showed consistent benefits across PD-L1 subgroups, though with higher grade 3+ adverse events (55% vs 31%). The study concludes that sac-TMT plus pembrolizumab may redefine first-line treatment for this patient population.
10.1016/S0140-6736(26)00968-2
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
LUNG CANCER · Q1 JOURNAL - RANK #19/108
These two randomized, prospective clinical trials (IMscin001 and IMscin002) evaluated the efficacy, safety, and immunogenicity of subcutaneous (SC) versus intravenous (IV) atezolizumab in patients with non-small cell lung cancer (NSCLC) across early-stage, locally advanced, or metastatic settings. Patients were randomized to receive either SC or IV atezolizumab every three weeks, with IMscin002 including a crossover and continuation period. Updated results show similar overall survival between groups in IMscin001 (median OS: 10.9 vs 10.1 months; hazard ratio: 1.00, 95% CI: 0.78-1.27) and 44.7% ongoing clinical benefit after cycle 16 in IMscin002. Both studies found comparable safety profiles, immunogenicity (20.0-21.1% anti-drug antibodies), and no new safety signals.
10.1016/j.lungcan.2026.109452
Early radiological response pattern predicts long-term response in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
CANCER IMAGING · Q1 JOURNAL - RANK #40/212
This prospective study evaluated early radiological response patterns in 122 NSCLC patients treated with immune checkpoint inhibitors (ICIs) from 2019 to 2023. Imaging per iRECIST assessed early sum-of-diameters (SoD) change at 8–12 weeks. Key findings: 32.8% achieved best overall response, 47.5% durable clinical benefit (DCB); early SoD reduction predicted DCB (AUC 0.764, p>0.05) and BOR (AUC 0.701, p<0.01). The authors conclude early radiological dynamics robustly predict outcomes and outperform laboratory biomarkers.
10.1186/s40644-026-01048-2
Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This Phase II FLARE-RT trial evaluated the efficacy of biological image-guided and risk-adaptive chemoradiation in 49 patients with unresectable NSCLC. Participants were stratified based on FDG-PET response, receiving either 60Gy or intensified doses between 74-90Gy. After a 52.3-month median follow-up, 1- and 2-year OS rates were reported as 81.6% and 54.2%, respectively, with 1- and 2-year PFS rates of 53.1% and 40.5%. The study demonstrated durable locoregional control, identified FDG-PET metrics as predictors of progression, and highlighted a potential benefit of adjunct durvalumab in reducing distant metastases without compromising local control, supporting its use in biomarker-guided NSCLC therapy.
10.1158/1078-0432.CCR-25-2626
Intrathecal Allogeneic B7-H3-targeted CAR γδ T Cells for Leptomeningeal Metastasis from Solid Tumors: Safety, Efficacy, and Immunological Dynamics in a Phase 1 Trial.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
Phase 1 trial NCT06592092 evaluated intrathecal QH104, an allogeneic B7-H3–targeted CAR γδ T-cell therapy, in three patients with B7-H3–positive leptomeningeal metastases from lung adenocarcinoma (n=2) or triple-negative breast cancer (n=1). Patients received 3 × 10^7 cells per infusion via lumbar puncture or Ommaya reservoir; primary endpoint was clinical response, with safety, overall survival, quality of life, and PK/PD as secondary endpoints. QH104 was generally well tolerated (no grade ≥4 TRAEs; one grade 3 ICANS resolving with care), all patients achieved stable disease at days 14 and 30 with symptom improvement in two, and CSF cytology converted and remained negative to day 30 in one baseline-positive case. CAR γδ T cells persisted in CSF for at least one week with increased IFN-γ, and single-cell sequencing indicated IFN-γ–associated immune remodeling.
10.1158/1078-0432.CCR-26-0738
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
The ORCHARD study was a phase II, biomarker-matched, prospective clinical trial evaluating osimertinib plus selumetinib in 16 patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) with BRAF alterations after progression on first-line osimertinib. Patients received osimertinib (80 mg daily) and selumetinib (75 mg twice daily) until disease progression or intolerable toxicity, with primary and secondary endpoints including objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. The ORR was 7% (80% CI < 1-25), median PFS was 3.4 months (95% CI 1.3-5.4), median OS was 14.0 months (95% CI 6.2-not calculable), and 69% experienced grade ≥3 adverse events. The combination showed minimal efficacy and a safety profile consistent with known drug effects, concluding further evaluation is not warranted.
10.1016/j.ejca.2026.116807
Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial.
PLOS MED · Q1 JOURNAL - RANK #13/332
This phase II randomized, open-label, two-cohort trial evaluated sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy (RT) intensity in 56 older and/or frail patients with stage III NSCLC ineligible for concurrent chemoradiotherapy (cCRT). The 1-year progression-free survival (PFS) was 84.3% for the standard RT group and 70.7% for the reduced RT group in the intention-to-treat set. Grade 3/4 adverse events occurred in 71.4% of standard RT patients and 53.6% of reduced RT patients, with grade 5 AEs in 10.7% and 3.6%, respectively. The results indicate that reduced RT combined with sequential chemo-immunotherapy is a feasible option, though limitations such as small sample size and non-comparative design necessitate further randomized trials.
10.1371/journal.pmed.1005111
Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial.
CHINESE MED J-PEKING · Q1 JOURNAL - RANK #23/332
This subgroup analysis of the phase 3 PAPILLON trial assessed amivantamab with carboplatin-pemetrexed versus carboplatin-pemetrexed alone in treatment-naïve Chinese mainland patients with advanced EGFR exon 20 insertion non-small cell lung cancer. In this randomized, open-label study, 87 patients were allocated to amivantamab plus chemotherapy (n = 39) or chemotherapy (n = 48); progression-free survival (PFS) by blinded independent central review was the primary endpoint. Median PFS was 12.3 months (95% CI 7.0-NE) with the combination versus 6.7 months (95% CI 4.2-8.6) with chemotherapy (HR 0.47, 95% CI 0.26-0.85, p = 0.0109); objective response rates were 71.8% vs 48.9% (OR 2.46, 95% CI 1.01-5.98). No new safety signals emerged and no patients discontinued amivantamab for toxicity, supporting the regimen as a first-line option for this molecularly defined NSCLC population.
10.1097/CM9.0000000000004134